Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taurolidine Urokinase for Prevention of Catheter Malfunction
NCT02036255Phase 3Completed
- Sponsor
- UZ Brussel
- Start
- May 2015
- Primary completion
- Jul 2017
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of urokinase in catheter dysfunction (2 arms), sponsored by UZ Brussel. Primary endpoint: Requirement of Urokinase at 6 months. Started May 2015; status: completed.
02
Drugs
urokinase
03
Conditions
catheter dysfunction
Beyond the preview
Go deeper on NCT02036255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036255.